Abstract
Candida krusei is an emerging pathogen, both in HIV negative immunocompromised patients and in HIV seropositive patients. Its onset appears to be due, at least in part, to the use of fluconazole. In HIV positive patients, a long term prophylactic use of fluconazole may select some less pathogenicCandida species, asC. krusei, that may determine persistent oral candidiasis and emerge as systemic pathogen. Itraconazole appears efficacious in treating AIDS-associatedC. krusei infections.
This is a preview of subscription content, log in via an institution to check access.
References
Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused byCandida krusei. J Clin Microbiol 1986; 24: 581–584.
McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due toCandida krusei: Report of ten cases of fungemia that include three cases of endophthalmitis. Clin Inf Dis 1992; 14: 472–478.
Person DA, Laughlin M, Tanner D, Perfect J, Goorman JP, Hathorn JW. Fluconazole andCandida krusei fungemia. N Engl J Med 1991; 325: 1515.
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Farp JE, Saral R. Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274–1277.
Coppola S, Montagna MT, Angarano G, Congedo P, Bellisario A, Monno L, Bramante LA, Barbuti S, Pastore G. Onset ofCandida krusei and other unusual yeasts in AIDS patients undergoing antifungal prophylaxis with azo-triazolic drugs. Micol Dermat 1993; 7: 141–144.
Fisher MA, Shen SH, Haddad J, Tarry WE. Comparison ofin vivo activity of fluconazole with that of amphotericin B againstCandida tropicalis, Candida glabrata, andCandida krusei. Antimicrob Agents and Chemother 1989; 33 (9): 1443–1446.
Galgiani JN. Susceptibility ofCandida albicans and other yeasts to fluconazole: Relation between in vitro and in vivo studies. Rev Infect Dis 1990; 12: S272-S275.
Denning DW, Tucher RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989; 86: 791–800.
Mcllroy MA. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis. J Infect Dis 1991; 163: 420–421.
Barchiesi F, Morbiducci V, Ancarani F, Arzeni A, Scalise G.Trichosporon beigelii fungaemia in an AIDS patient. AIDS 1993; 7: 139–140.
Coppola S, Angarano G, Montagna MT, Congedo P, Bellisario A, Monno L, Infante G, Pastore G.Trichosporon beigelii infection in AIDS patients undergoing antifungal prophylaxis. J Mycol Med 1993; 3: 169–171.
Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Int Med 1988; 108: 88–100.
Jenkins RE, Peters BS, Pinching AJ. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS 1991; 5 (12): 1540–1542.
Klotz SA. Fungal adherence to the vascular compartment: A critical step in the pathogenesis of disseminated candidiasis. Clin Infect Dis 1992; 14: 340–347.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coppola, S., Angarano, G., Montagna, M.T. et al. Efficacy of itraconazole in treating AIDS-associated infections due toCandida krusei . Eur J Epidemiol 11, 243–244 (1995). https://doi.org/10.1007/BF01719497
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01719497